Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, People's Republic of China.
Graduate School of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Drug Des Devel Ther. 2020 Sep 15;14:3731-3746. doi: 10.2147/DDDT.S272355. eCollection 2020.
Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. is a commonly used Chinese medicinal herb. Previous studies have shown that has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of , which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development.
心血管疾病(CVD)是全球头号死因,一直是临床和科学研究的重点。由于每年的死亡人数众多,因此必须找到安全有效且副作用最小的替代疗法。中药(TCM)在治疗 CVD 方面有着悠久的历史和重要影响。药物天然活性成分的作用方式和新药的开发是目前 TCM 研究的热门话题。黄芪是一种常用的中药。先前的研究表明,黄芪具有抗肿瘤特性,可调节代谢、增强免疫力和强心。黄芪甲苷 IV(AS-IV)是黄芪的活性成分,在心血管疾病中具有突出作用。AS-IV 可预防缺血和缺氧心肌细胞损伤,抑制心肌肥大和心肌纤维化,增强心肌收缩力,改善舒张功能障碍,减轻血管内皮功能障碍,促进血管生成。它还可以调节血糖和血脂水平,降低心血管疾病的风险。本文综述了近年来 AS-IV 干预心血管疾病的机制,以期为未来的研究和新药开发提供参考。
Drug Des Devel Ther. 2020
Biomed Pharmacother. 2023-12
Biomed Pharmacother. 2020-6
J Ethnopharmacol. 2023-4-6
Biomed Pharmacother. 2022-12
J Tradit Chin Med. 2013-6
Int Urol Nephrol. 2024-8
Mol Cancer. 2025-8-1
Nutrients. 2025-4-8
Front Pharmacol. 2024-12-11
Int J Mol Sci. 2020-4-30
Nutr Metab Cardiovasc Dis. 2020-2-4
J Ethnopharmacol. 2019-11-15
Artif Cells Nanomed Biotechnol. 2019-12